|Bid||6.95 x 3100|
|Ask||6.96 x 4000|
|Day's range||6.33 - 7.00|
|52-week range||2.87 - 17.85|
|Beta (5Y monthly)||1.38|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.33|
bluebird (BLUE) posts a narrower-than-expected loss in the second quarter. However, sales miss estimates.
Bluebird (BLUE) delivered earnings and revenue surprises of 1.53% and 76.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SOMERVILLE, Mass, August 04, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the second quarter ended June 30, 2022, and shared recent operational progress.